The controversial role of ABC transporters in clinical oncology. (Q37941758)

PubMed publication ID

25 August 2017

1 reference

title

The controversial role of ABC transporters in clinical oncology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

5

Susan E Bates

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

author name string

Akina Tamaki

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

Caterina Ierano

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

Gergely Szakacs

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

publication date

1 September 2011

1 reference

PubMed publication ID

21967059

25 August 2017

published in

Essays in Biochemistry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

page(s)

209-232

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Substrate recognition and transport by multidrug resistance protein 1 (ABCC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

ABC transporters in the balance: is there a role in multidrug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Low levels of ABCG2 expression in adult AML blast samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

BCRP mRNA expression v. clinical outcome in 40 adult AML patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Effect of valspodar on the pharmacokinetics of unbound paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Pheophorbide a is a specific probe for ABCG2 function and inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Pharmacological strategies for overcoming multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

CNS metastasis: an old problem in a new guise

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBSE0500209

Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRP1.

21 January 2018

1 reference

12 December 2020

Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy

1 reference

12 December 2020

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

1 reference

12 December 2020

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

1 reference

12 December 2020

Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.

1 reference

12 December 2020

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study

1 reference

12 December 2020

Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma

1 reference

12 December 2020

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

12 December 2020

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

1 reference

12 December 2020

Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.

1 reference

12 December 2020

Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy

1 reference

12 December 2020

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

1 reference

12 December 2020

Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

1 reference

12 December 2020

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy

1 reference

12 December 2020

Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers

1 reference

12 December 2020

Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833

1 reference

12 December 2020

A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients

1 reference

12 December 2020

Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS

1 reference

12 December 2020

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies

1 reference

12 December 2020

Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

1 reference

12 December 2020

Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer

1 reference

12 December 2020

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

1 reference

12 December 2020

Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine

1 reference

12 December 2020

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

1 reference

12 December 2020

Identifiers

DOI

10.1042/BSE0500209

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6944313&resulttype=core&format=json

13 May 2020

PubMed publication ID

21967059

1 reference